For the roughly 600,000 people worldwide diagnosed with bladder cancer each year, the current treatment path can be brutal. After surgically removing tumors, patients often face chemotherapy or immunotherapy regimens that frequently fail, sometimes leading to the ultimate intervention: complete bladder removal, a life-altering surgery with significant complications.
But researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center may have opened a door to something better. In a study published in the Journal of Experimental Medicine, their team developed genetically engineered CAR T cells that specifically target bladder cancer cells—and crucially, they found that delivering these cells directly into the bladder via catheter produced dramatically better results than the standard intravenous approach.
The key innovation was twofold. First, the researchers engineered CAR T cells to recognize a protein called MUC16, which is highly expressed on the surface of many bladder cancer cells—including treatment-resistant types—but largely absent from healthy bladder tissue and other organs. Second, they delivered these targeted cells directly to the tumor site using a catheter, a method called intravesical delivery.
In tests on mice implanted with human bladder cancer cells, the difference was striking. When the CAR T cells were administered through an IV line, they were ineffective. But when delivered intravesically via catheter, the cells significantly reduced tumor growth and extended survival. Even more promising: because the therapy stays contained within the bladder, it cannot spread to other parts of the body, minimizing the risk of off-target side effects that have complicated CAR T approaches to solid tumors.
"Using a compartmentalized delivery system allows us to overcome this hurdle and hopefully come one step closer to broader use of CAR and transgenic T cells for common solid tumors, like bladder cancer," said Professor Jedd Wolchok, co-leader of the study at Weill Cornell Medicine.
For patients like those Parwiz Abrahimi sees in his practice—the study's first author, now a urologic oncologist at Cedars-Sinai in Los Angeles—this could represent a fundamental shift. "For patients facing high-risk bladder cancer, options have historically been limited, highly morbid and life-altering," he said. "This reality has driven a critical, renewed interest in developing effective bladder-sparing approaches."
Professor Taha Merghoub, another co-leader of the study, emphasized the approach's potential breadth: "This could be useful for both initial treatment of bladder cancer as well as treatment-refractory subsets of tumors, offering an attractive therapeutic option for patients who may have limited therapeutic alternatives besides bladder removal."
The findings establish MUC16 as a clinically relevant target and intravesical delivery as a feasible, readily implementable strategy. While human trials remain ahead, the research offers real hope that bladder-sparing cancer treatment may become an reality for patients who today face far grimmer choices.